The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Cardiac amyloidosis care across Europe: areas of greatest variation in diagnosis and management
Luuk Kieviet, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses findings from a key opinion leader survey exploring the areas of greatest variation in cardiac amyloidosis care across Europe. Dr Kieviet highlights differences in disease awareness, access to diagnostic tools, treatment availability, and clinical decision-making between European centers. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that it will be on awareness. So do cardiologists think of cardiac amyloidosis? And I think this has increased tremendously in the past years. Especially, well, I know it’s from the Netherlands, but we have seen so many more diagnoses than before. But there will be differences between the centers also treatment options, so for in the Netherlands we have the familial and now also our amyloidosis specialists, and I know from Denmark, there they only have amyloidosis specialists, and there’s why is that – it’s also because of governmental or things like that...
I think that it will be on awareness. So do cardiologists think of cardiac amyloidosis? And I think this has increased tremendously in the past years. Especially, well, I know it’s from the Netherlands, but we have seen so many more diagnoses than before. But there will be differences between the centers also treatment options, so for in the Netherlands we have the familial and now also our amyloidosis specialists, and I know from Denmark, there they only have amyloidosis specialists, and there’s why is that – it’s also because of governmental or things like that. So treatment decisions, treatment options, those are already also really, they probably will be different, and also what, how can you, how do you have the means to diagnose, so you have the the bone scintigraphy, the echo, the CMR. We know that in a lot of countries, CMR isn’t that easily available. So those will be things that I think will really come out as differences between the countries.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
